Prévisions

L'objectif de cours moyen des analystes est de 5,17 € (+126,75 %). La médiane est de 5,17 € (+126,75 %).

Acheter	11
Conserver	3
Vendre	0

Actualités Accéder au fil d'actualités

Ovid Therapeutics emphasizes KCC2 program and epilepsy pipeline as value drivers

At the Cantor conference Ovid Therapeutics presented its two‑pillar strategy centered on the KCC2 program (OV4071) and the epilepsy pipeline (notably OV329), and views KCC2 as the main long‑term value driver if early human data confirm preclinical results. OV4071 is in phase I; a ketamine challenge and several biomarker studies are intended to link earlier animal data with human data. OV329 is being positioned to differentiate in focal-onset and pediatric epilepsies; proof‑of‑concept data and a phase II are planned for 2024/2025. Ovid also retains rights to milestone/license payments from Soticlestat, which represents additional upside without development risk. » Plus sur de.investing.com
Ovid Therapeutics names Kevin Norrett chief business officer, promotes key executives

Ovid Therapeutics appointed Kevin Norrett as chief business officer to lead business development and strategic partnerships. Charles Carter was promoted to CFO, succeeding Jeffrey Rona who will remain a long-term advisor through 2027, and Victoria Fort was promoted to chief strategy officer. The company reported Q1 EPS of (12c), said development programs are on track, and expects to be well capitalized into 2029. » Plus sur finance.yahoo.com
Ovid Therapeutics appoints Kevin Norrett as chief business officer and restructures leadership team

Ovid Therapeutics brings in Kevin Norrett as chief business officer to lead business and corporate development and strategic partnerships. Charles Carter was promoted to chief financial officer; Jeffrey Rona will remain on board as an advisor through 2027. Eliseo Salinas joins as executive R&D advisor and Victoria Fort was promoted to chief strategy officer; Fort led financing rounds that secure the company’s cash runway through 2029. The company is developing, among others, OV329 for treatment-resistant focal-onset seizures and OV4071 for central nervous system disorders. » Plus sur de.investing.com

Données financières de l'entreprise

Au dernier trimestre, OVID THERAPEUTICS DL-,001 a réalisé un chiffre d'affaires de 642,26 k € et un bénéfice net de -13,15 M €

(EUR)	juin 2026	YoY
Chiffre d'affaires	642,26 k	87,93 %
Bénéfice brut	642,26 k	87,93 %
Bénéfice net	-13,15 M	230,93 %
EBITDA	-13,48 M	246,47 %

Données fondamentales

Indicateur	Valeur
Capitalisation boursière	442,29 M €
Nombre d'actions	186,64 M
Plus haut/bas sur 52 semaines	2,68 € - 0,97 €
Dividendes	Non
Bêta	0,25
Ratio P/E	-5,73
Ratio PEG	0,16
Ratio P/B	0,97
Ratio P/S	324,23

Profil de l'entreprise

Ovid Therapeutics Inc. ist ein biopharmazeutisches Unternehmen, das wirksame Medikamente für Patienten und Familien mit neurologischen Erkrankungen in den Vereinigten Staaten entwickelt. Das Unternehmen entwickelt OV101, einen Arzneimittelkandidaten, der sich in der klinischen Phase 2A zur Behandlung des fragilen X-Syndroms befindet, OV329, einen GABA-Aminotransferase-Hemmer zur Behandlung von Anfällen im Zusammenhang mit tuberöser Sklerose und infantilen Spasmen, und OV350, ein kleines Molekül zur Behandlung von Epilepsien. Darüber hinaus entwickelt das Unternehmen OV882, eine Short-Hairpin-RNA-Gentherapie zur Behandlung des Angelman-Syndroms, und OV815 zur Behandlung von neurologischen Störungen im Zusammenhang mit der Kinesin-Protein-Familie. Das Unternehmen hat Lizenz- und Kooperationsvereinbarungen mit Healx, AstraZeneca AB, H. Lundbeck A/S und der Northwestern University sowie mit Marinus Pharmaceuticals, Inc. Das Unternehmen wurde im Jahr 2014 gegründet und hat seinen Hauptsitz in New York, New York.

Nom	OVID THERAPEUTICS DL-,001
PDG	Margaret Alexander
Siège social	New York City, ny États-Unis
Site web	ovidrx.com
Secteur	Matériaux
Industrie	Produits chimiques
Introduction en bourse	05/05/2017
Employés	23